In a new study published in JAMA Network Open, researchers assessed whether individuals diagnosed with advanced breast cancer are more likely to have prevalent cardiovascular disease (CVD) compared with those diagnosed with early-stage breast cancer.
The study used data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked databases from 2009 to 2020 and included a cohort of 19,292 control-matched individuals diagnosed with invasive breast cancer. The participants were at least 66 years old, with a median age of 73 years (interquartile range, 70-79); 9,478 individuals (49.1%) had prevalent CVD.
Propensity score–matched, multivariable-adjusted models revealed that individuals with locally advanced or metastatic breast cancer at diagnosis had statistically significantly increased odds of prevalent CVD (odds ratio [OR], 1.10; 95% CI, 1.03-1.17; P=.007). This association was observed among individuals with hormone receptor–positive (OR, 1.11; 95% CI, 1.03-1.19; P=.006) breast cancer but not those with hormone receptor–negative (OR, 1.02; 95% CI, 0.86-1.21; P=.83) breast cancer. ORs were directionally consistent on separate examination of locally advanced (OR, 1.09; 95% CI, 1.02-1.17; P=.02) and metastatic (OR, 1.20; 95% CI, 0.94-1.54; P=.15) disease, among all receptor subtypes.
“This retrospective case-control study found an association between prevalent CVD and more advanced stage of breast cancer at diagnosis, independent of factors associated with delayed diagnosis and shared risk. Further studies are needed to determine whether individuals with CVD would benefit from personalized screening approaches,” the researchers concluded.
Source
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.